A 3-O-sulfated heparan sulfate binding peptide preferentially targets herpes simplex virus 2-infected cells

Journal of Virology

Volumn 86, Issue 12, 2012, Pages 6434-6443

  Ali, Mohamed M ^a,b   Karasneh, Ghadah A ^a   Jarding, Min Jung ^a,d   Tiwari, Vaibhav ^a,c   Shukla, Deepak ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c MIDWESTERN UNIVERSITY   (United States)

^d CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; G2 PEPTIDE; HEPARAN SULFATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS ENTRY;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; FEMALE; HEPARITIN SULFATE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; MICE; MICE, INBRED BALB C; PEPTIDES; RECEPTORS, VIRUS; VIRUS INTERNALIZATION;

HERPES; HUMAN HERPESVIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84864010392     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00433-12     Document Type: Article

References (51)

1. Akhtar J, et al. 2008. HVEM and nectin-1 are the major mediators of herpes simplex virus 1 (HSV-1) entry into human conjunctival epithelium. Invest. Ophthalmol. Vis. Sci. 49:4026-4035.
2. Albiol Matanic VC, Castilla V. 2004. Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus. Int. J. Antimicrob. Agents 23:382-389.
3. Andersen JH, Jenssen H, Gutteberg TJ. 2003. Lactoferrin and lactoferricin inhibit herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir. Antiviral Res. 58:209 -215.
4. Andersen JH, Jenssen H, Sandvik K, Gutteberg TJ. 2004. Anti-HSV activity of lactoferrin and lactoferricin is dependent on the presence of heparan sulphate at the cell surface. J. Med. Virol. 74:262-271.
5. Araki-Sasaki K, et al. 1995. An SV40-immortalized human corneal epithelial cell line and its characterization. Invest. Ophthalmol. Vis. Sci. 36: 614-621.
6. Arii J, et al. 2010. Non-muscle myosin IIA is a functional entry receptor for herpes simplex virus-1. Nature 467:859-862.
7. Bernstein DI, Ireland J, Bourne N. 2000. Pathogenesis of acyclovirresistant herpes simplex type 2 isolates in animal models of genital herpes: models for antiviral evaluations. Antiviral Res. 47:159 -169.
8. Bhattacharjee PS, Neumann DM, Hill JM. 2009. A human apolipoprotein E mimetic peptide effectively inhibits HSV-1 TK-positive and TKnegative acute epithelial keratitis in rabbits. Curr. Eye Res. 34:99 -102.
9. Brady RC, Bernstein DI. 2004. Treatment of herpes simplex virus infections. Antiviral Res. 61:73- 81.
10. Cardin AD, Weintraub HJ. 1989. Molecular modeling of proteinglycosaminoglycan interactions. Arteriosclerosis 9:21-32.
11. Carfí A, et al. 2001. Herpes simplex virus glycoprotein D bound to the human receptor HveA. Mol. Cell 8:169 -179.
12. Carter NM, Ali S, Kirby JA. 2003. Endothelial inflammation: the role of differential expression of N-deacetylase/N-sulphotransferase enzymes in alteration of the immunological properties of heparan sulphate. J. Cell Sci. 116:3591-3600.
13. Compton T, Nowlin DM, Cooper NR. 1993. Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology 193:834-841.
14. de Jong MA, de Witte L, Taylor ME, Geijtenbeek TB. 2010. Herpes simplex virus type 2 enhances HIV-1 susceptibility by affecting Langerhans cell function. J. Immunol. 185:1633-1641.
15. Eizuru Y. 2003. Development of new antivirals for herpesviruses. Antivir. Chem. Chemother. 14:299 -308.
16. Esko JD, Lindahl U. 2001. Molecular diversity of heparan sulfate. J. Clin. Invest. 108:169 -173.
17. Geraghty RJ, Krummenacher C, Cohen GH, Eisenberg RJ, Spear PG. 1998. Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science 280:1618 -1620.
18. Gruenheid S, Gatzke L, Meadows H, Tufaro F. 1993. Herpes simplex virus infection and propagation in a mouse L cell mutant lacking heparan sulfate proteoglycans. J. Virol. 67:93-100.
19. Herold BC, WuDunn D, Soltys N, Spear PG. 1991. Glycoprotein C of herpes simplex virus type 1 plays a principal role in the adsorption of virus to cells and in infectivity. J. Virol. 65:1090 -1098.
20. Jacquet A, et al. 1998. The varicella zoster virus glycoprotein B (gB) plays a role in virus binding to cell surface heparan sulfate proteoglycans. Virus Res. 53:197-207.
21. Karasneh GA, Ali M, Shukla D. 2011. An important role for syndecan-1 in herpes simplex virus type-1 induced cell-to-cell fusion and virus spread. PLoS One 6:e25252. doi:10.1371/journal.pone.0025252.
22. Kimura C, Oike M. 2008. Heparan sulfate proteoglycan is essential to thrombin-induced calcium transients and nitric oxide production in aortic endothelial cells. Thromb. Haemost. 100:483- 488.
23. Krummenacher C, et al. 1999. The first immunoglobulin-like domain of HveC is sufficient to bind herpes simplex virus gD with full affinity, while the third domain is involved in oligomerization of HveC. J. Virol. 73: 8127-8137.
24. Liu J, Shworak NW, Fritze LM, Edelberg JM, Rosenberg RD. 1996. Purification of heparan sulfate D-glucosaminyl 3-O-sulfotransferase. J. Biol. Chem. 271:27072-27082.
25. Liu J, et al. 1999. Expression of heparan sulfate D-glucosaminyl 3-Osulfotransferase isoforms reveals novel substrate specificities. J. Biol. Chem. 274:5185-5192.
26. Martens, MG, Fife KH, Leone PA, Dix LP, Brennan CA. 2009. Once daily valacyclovir for reducing viral shedding in subjects newly diagnosed with genital herpes. Infect. Dis. Obstet. Gynecol. 2009:105376.
27. Montgomery RI, Warner MS, Lum BJ, Spear PG. 1996. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 87:427- 436.
28. Muggeridge MI. 2000. Characterization of cell-cell fusion mediated by herpes simplex virus 2 glycoproteins gB, gD, gH and gL in transfected cells. J. Gen. Virol. 81:2017-2027.
29. Nilsson BL, Soellner MB, Raines RT. 2005. Chemical synthesis of proteins. Annu. Rev. Biophys. Biomol. Structure 34:91-118.
30. O'Donnell CD, Shukla D. 2009. A novel function of heparan sulfate in the regulation of cell-cell fusion. J. Biol. Chem. 284:29654 -29665.
31. O'Donnell CD, Tiwari V, Oh MJ, Shukla D. 2006. A role for heparan sulfate 3-O-sulfotransferase isoform 2 in herpes simplex virus type 1 entry and spread. Virology 346:452- 459.
32. Oh MJ, Akhtar J, Desai P, Shukla D. 2010. A role for heparan sulfate in viral surfing. Biochem. Biophys. Res. Commun. 391:176 -181.
33. Pertel PE, Fridberg A, Parish ML, Spear PG. 2001. Cell fusion induced by herpes simplex virus glycoproteins gB, gD, and gH-gL requires a gD receptor but not necessarily heparan sulfate. Virology 279:313-324.
34. Satoh T, et al. 2008. PILRalpha is a herpes simplex virus-1 entry coreceptor that associates with glycoprotein B. Cell 132:935-944.
35. Scanlan PM, Tiwari V, Bommireddy S, Shukla D. 2003. Cellular expression of gH confers resistance to herpes simplex virus type-1 entry. Virology 312:14 -24.
36. Shukla D, et al. 1999. A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell 99:13-22.
37. Shukla D, Spear PG. 2001. Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry. J. Clin. Invest. 108:503-510.
38. Shworak NW, et al. 1999. Multiple isoforms of heparan sulfate Dglucosaminyl 3-O-sulfotransferase. Isolation, characterization, and expression of human cDNAs and identification of distinct genomic loci. J. Biol. Chem. 274:5170 -5184.
39. Sinha S, Cheshenko N, Lehrer RI, Herold BC. 2003. NP-1, a rabbit alpha-defensin, prevents the entry and intercellular spread of herpes simplex virus type 2. Antimicrob. Agents Chemother. 47:494 -500.
40. Stanberry L, et al. 1999. New developments in the epidemiology, natural history and management of genital herpes. Antiviral Res. 42:1-14.
41. Tiwari V, O'Donnell CD, Oh MJ, Valyi-Nagy T, Shukla D. 2005. A role for 3-O-sulfotransferase isoform-4 in assisting HSV-1 entry and spread. Biochem. Biophys. Res. Commun. 338:930 -937.
42. Tiwari V, ten Dam GB, Yue BY, van Kuppevelt TH, Shukla D. 2007. Role of 3-O-sulfated heparan sulfate in virus-induced polykaryocyte formation. FEBS Lett. 581:4468-4472.
43. Tiwari V, Liu J, Valyi-Nagy T, Shukla D. 2011. Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo. J. Biol. Chem. 286:25406 -25415.
44. Tyagi M, Rusnati M, Presta M, Giacca M. 2001. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J. Biol.Chem.276:3254-3261.
45. Warner MS, et al. 1998. A cell surface protein with herpesvirus entry activity (HveB) confers susceptibility to infection by mutants of herpes simplex virus type 1, herpes simplex virus type 2, and pseudorabies virus. Virology 246:179 -189.
46. Weller S, et al. 1993. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin. Pharmacol. Ther. 54:595- 605.
47. Wigdahl B, Smith CA, Traglia HM, Rapp F. 1984. Herpes simplex virus latency in isolated human neurons. Proc. Natl. Acad. Sci. U. S. A. 81:6217- 6221.
48. WuDunn D, Spear PG. 1989. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J. Virol. 63:52-58.
49. Xia G, et al. 2002. Heparan sulfate 3-O-sulfotransferase isoform 5 generates both an antithrombin-binding site and an entry receptor for herpes simplex virus, type 1. J. Biol. Chem. 277:37912-37919.
50. Xu D, et al. 2005. Characterization of heparan sulphate 3-Osulphotransferase isoform 6 and its role in assisting the entry of herpes simplex virus type 1. Biochem. J. 385:451- 459.
51. Yasin B, et al. 2000. Evaluation of the inactivation of infectious herpes simplex virus by host-defense peptides. Eur. J. Clin. Microbiol. Infect. Dis. 19:187-194.